BridgeBio Pharma Inc
$ 80.09
-2.50%
31 Jul - close price
- Market Cap 15,686,527,000 USD
- Current Price $ 80.09
- High / Low $ 82.40 / 79.45
- Stock P/E N/A
- Book Value -11.64
- EPS -3.64
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -17.90 %
- 52 Week High 93.42
- 52 Week Low 42.09
About
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Analyst Target Price
$105.26
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-10-29 | 2025-08-05 | 2025-04-29 | 2025-02-20 | 2024-11-12 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.84 | -0.9389 | -0.72 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -1.01 | -0.12 | -0.96 | -1.08 | -0.96 |
| Estimated EPS | -0.62 | -0.716 | -0.78 | -0.6 | -0.89 | -1.09 | -0.98 | -0.94 | -0.54 | -0.91 | -0.89 | -0.87 |
| Surprise | -0.22 | -0.2229 | 0.06 | -0.35 | -0.0988 | -0.2844 | 0.1204 | -0.07 | 0.42 | -0.05 | -0.19 | -0.09 |
| Surprise Percentage | -35.4839% | -31.1313% | 7.6923% | -58.3333% | -11.1011% | -26.0917% | 12.2857% | -7.4468% | 77.7778% | -5.4945% | -21.3483% | -10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.63 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2026-08-01 06:10:42
BlackRock, Inc. significantly reduced its stake in BridgeBio Pharma Inc (BBIO) by selling over 4.4 million shares at $74.48 each on June 30, 2026. Despite this reduction, BridgeBio's stock has seen a 7.53% gain since the transaction, and its GF Value suggests it's trading at a significant discount, though with warnings of a "Possible Value Trap" due to weak financial health. The move is viewed as a portfolio rebalancing by BlackRock, which maintains a vast and diversified investment strategy.
2026-08-01 02:10:03
BlackRock, Inc. significantly reduced its stake in BridgeBio Pharma Inc (BBIO) by selling over 4.4 million shares, representing a 31.49% change in its holdings. While BridgeBio's stock has seen a 7.53% gain since the transaction and exhibits strong growth metrics, its financial health remains concerning with a "Possible Value Trap" warning from GuruFocus. This move by BlackRock appears to be a portfolio rebalancing rather than a negative outlook, highlighting the complex investment thesis for BridgeBio.
2026-07-31 05:40:19
BridgeBio Pharma (BBIO) has received FDA New Drug Application acceptance for encaleret, following positive Phase 3 data and active launch preparations. Despite this clinical progress and strong share price performance over the last year, Simply Wall St's "Most Popular Narrative" suggests the stock is 229% overvalued with a fair value of $25, while their DCF model indicates it is 74.4% undervalued at $320.71. This discrepancy highlights varied investor perspectives on the company's valuation given its regulatory success and upcoming product launches.
2026-07-29 19:40:41
This article provides key metrics for the BridgeBio Pharma, Inc. 0.75% 01-FEB-2033 bond (US10806XAK8), traded on the Frankfurt Stock Exchange. It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. The company, BridgeBio Pharma, Inc., is described as focusing on transformative medicines for Mendelian diseases.
2026-07-29 19:11:46
The article provides a comprehensive stock analysis of BridgeBio Pharma Inc (BBIO), highlighting its strong fundamentals, high growth potential, and "Buy" ratings from analysts, with a target price of 105.16. Despite positive market performance, technical indicators suggest a sideways trading pattern between support and resistance levels. The company is involved in developing transformative medicines for genetic diseases, with a robust pipeline of development programs.
2026-07-29 17:39:55
BridgeBio Pharma Inc. is set to report its second-quarter earnings, as the rare-disease biotech company transitions into a multi-product commercial operation. Analysts anticipate a loss of $0.60 per share on revenues of $222.2 million, with strong buy ratings and an implied 23% upside from its current share price. Investors will focus on the commercial performance of Attruby and regulatory progress for other pipeline drugs, alongside balance sheet management strategies given upcoming convertible note maturities.
